CVKD: Acquires Factor XIa Inhibitors
On September 15, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced the acquisition of assets from eXIthera Pharmaceuticals that includes a...
299 Views
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin
On May 8, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for the first quarter of 2025 and provided a business update. The...
237 Views
CVKD: Preparing for Phase 3 Trial of Tecarfarin
On March 13, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for 2024 and provided a business update. The company has been...
227 Views
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial
On March 4, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced a collaboration agreement with Abbott to support the company's pivotal TECarfarin...
439 Views
CVKD: Recent Financings Raise 9.8 Million
On November 7, 2024, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for the third quarter of 2024 and provided a business...
252 Views